NCT00228488已完成2 期
Phase II Study of Iressa With/Without Concurrent Chemoradiotherapy in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma and to Study the Effect of Iressa™ (ZD1839) on Tumour Gene Expression Profiles ®
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- To study the effect of Iressa on gene expression profiles in patients with head and neck cancer
研究概览
简要总结
Two different patient populations will be targeted for this study. The first population (SP1) will include patients with recurrent/metastatic head and neck cancers, excluding salivary gland carcinomas. The second population (SP2) will include treatment-naïve patients with locally advanced squamous cell head and neck cancer (SCHNC).
SP1 will be treated with palliative intent and the patients can be treatment-naïve or have received prior chemotherapy. Study treatment will consist of Iressa (gefitinib) alone.
SP2 will be treated with radical intent. The patients must be treatment-naïve and study treatment will consist of induction Iressa for 3 weeks followed by a combination of Iressa plus cisplatin and concurrent irradiation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed carcinoma of the head and neck (excluding salivary gland and nasopharyngeal carcinoma), namely squamous cell or undifferentiated carcinoma
- •Recurrent/metastatic disease that is not amenable to cure
- •Accessible tumour site for repeat tumour samplings
- •Patients must be agreeable to repeated tumour samplings.
- •Measurable disease sites by computed tomography (CT) imaging is preferred but not mandatory.
- •Adequate performance status of ECOG 0 - 2
- •Life expectancy of at least 3 months
- •Written informed consent to participate in the study
排除标准
- •Prior treatment with tyrosine kinase inhibitor or anti-epidermal growth factor receptor (EGFR) therapy
- •Refusal for repeated tumour samplings
- •Tumour site deemed unsafe for repeated samplings due to risk of bleeding
- •In the opinion of the investigator, any evidence of severe or uncontrolled systemic disease (eg. unstable or uncompensated respiratory disorder, cardiac failure, hepatic decompensation, renal failure, uncontrolled metabolic disorders such as diabetes mellitus, or uncontrolled significant infections)
- •Any bleeding disorders
- •Pregnancy or breast-feeding (women of child-bearing potential)
- •Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical carcinoma-in-situ
- •Inclusion Criteria for SP2:
- •Histologically confirmed carcinoma of the head and neck (excluding salivary gland and nasopharyngeal carcinoma), namely squamous cell carcinoma or undifferentiated carcinoma
- •Locally advanced disease (stage III/IV) without distant metastases, not amenable to curative resection, or patient refusal for surgery
- •Accessible primary site for repeat tumour samplings
- •Patients agreeable to repeated tumour samplings
- •Evaluable and/or measurable disease sites on CT scans
- •Adequate performance status of ECOG 0 - 1
- •Written informed consent to participate in the study
- •Exclusion Criteria for SP2:
- •Presence of distant metastases
- •Prior treatment with EGFR-targeted therapy, or chemotherapy or radiotherapy to head and neck region
- •Refusal for repeated tumour samplings
- •Tumour site deemed unsafe for repeated samplings due to risk of bleeding
- •Common toxicity criteria (CTC) grade 2 or greater pre-existing motor or sensory neuropathy
- •In the opinion of the investigator, any evidence of severe or uncontrolled systemic disease (eg. unstable or uncompensated respiratory disorder, cardiac failure, hepatic decompensation, renal failure, uncontrolled metabolic disorders such as diabetes mellitus, or uncontrolled significant infections)
- •Any bleeding disorders
- •Absolute neutrophil count of less than 1000/mm3, and platelet count of less than 100,000/mm3
- •Serum bilirubin greater than 2 times the upper limit of normal range (ULNR)
- •Serum alanine aminotransferase (ALT) and serum aspartate amino transferase (AST) greater than 2.5 times ULNR
- •Serum creatinine greater than 143 umol/litre
- •Pregnancy or breast-feeding (women of child-bearing potential)
- •Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical carcinoma-in-situ
结局指标
主要结局
To study the effect of Iressa on gene expression profiles in patients with head and neck cancer
次要结局
- To study the efficacy of Iressa as monotherapy as first line or after failing prior platinum-based regimen in patients with recurrent/metastatic head and neck carcinomas
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Iressa v BSC (Best Supportive Care) in First Line NSCLCNSCLCNCT00259064AstraZeneca216
已完成
2 期
Iressa as a First-Line Treatment in Chemonaive Patients With Inoperable Non-Small Cell Lung CancerNon-Small Cell Lung CancerNCT00173875National Taiwan University Hospital108
已完成
2 期
A Study of IRESSA in Relapsed and Refractory Small Cell Lung CancerSmall Cell Lung CancerNCT00298688AstraZeneca56
已完成
2 期
Concomitant Association of Ultrafractionated Brain Irradiation - Temozolomide in Inoperable Primary Glioblastoma MultiformeGlioblastoma MultiformeNCT03310372Central Hospital, Nancy, France46
已完成
1 期
Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.Solid TumorBreast CancerNCT03944499Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.161